Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Green, Lawrence J. ^{[2
]}

Lebwohl, Mark G. ^{[3
]}

Yamauchi, Paul S. ^{[4
]}

Lin, Tina ^{[5
]}

Martin, Gina ^{[6
]}

Pillai, Radhakrishnan ^{[6
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR 97223 USA

[2] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA

[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[4] Clin Sci Inst, Santa Monica, CA USA

[5] Ortho Dermatol, Bridgewater, NJ USA

[6] Bausch Hlth Amer Inc, Petaluma, CA USA

来源：

JOURNAL OF DRUGS IN DERMATOLOGY | 2019年 / 18卷 / 03期

关键词：

PHYSICIAN GLOBAL ASSESSMENT; BODY-SURFACE AREA; APREMILAST; SAFETY;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：297 / 299

页数：3

共 50 条

[31] Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis
Tanghetti, Emil A.
Werschler, William Philip
Lain, Edward
Guenin, Eric
Harris, Susan
Loncaric, Anya
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (03) : 272 - 279
[32] THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
Lozano-Ortega, G.
Rogula, B.
Gaudet, V
Mickle, A.
Johnston, K.
Barbeau, M.
VALUE IN HEALTH, 2019, 22 : S363 - S363
[33] Treatment of moderate-to-severe acne with once-daily tazarotene 0.045% lotion in pediatric patients: Pooled analysis of two phase 3 studies
Eichenfield, L. F.
Tanghetti, E.
Guenin, E.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S82 - S82
[34] Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials
Gold, Linda Stein
Lebwohl, Mark G.
Sugarman, Jeffrey L.
Pariser, David M.
Lin, Tina
Martin, Gina
Pillai, Radhakrishnan
Israel, Robert
Ramakrishna, Tage
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 287 - 293
[35] A CANADIAN NETWORK META-ANALYSIS OF THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Lozano-Ortega, G.
Rogula, B.
Gaudet, V
Mickle, A.
Johnston, K.
Barbeau, M.
VALUE IN HEALTH, 2020, 23 : S362 - S362
[36] New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis
Eichenfield, Lawrence F.
Tanghetti, Emil A.
Guenin, Eric
Martin, Gina
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (06) : 602 - 610
[37] Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion
Abduelmula, Abrahim
Gooderham, Melinda J.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (03) : 293 - 294
[38] Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants
Cook-Bolden, Fran E.
Hebert, Adelaide A.
Guenthner, Scott T.
Kang, Robert
Martin, Gina
Jacobson, Abby
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 747 - 754
[39] Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne
Del Rosso, James
Gold, Linda Stein
Tyring, Stephen
Zeichner, Joshua
Callender, Valerie
Draelos, Zoe
Werschler, William
Cook-Bolden, Fran
Guenin, Eric
JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (10) : 1061 - 1069
[40] Long-term management of moderate to severe plaque psoriasis: Maintenance of treatment success following cessation of fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in patients with baseline body surface area of 6%-12%
Gold, Linda Stein
Weiss, Jonathan S.
Green, Lawrence J.
Kircik, Leon
Lin, Tina
Harris, Susan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB36 - AB36

← 1 2 3 4 5 →